A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
Conditions
Hyperphosphatemia · Chronic Kidney Disease Requiring Chronic Dialysis · End Stage Renal Disease on Dialysis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Apogee Clinical Research, LLC, Huntsville, Alabama, United States
California Institute of Renal Research, Chula Vista, California, United States
Academic Medical Research Institute, Los Angeles, California, United States
R1 Therapeutics Clinical Trial Site, San Dimas, California, United States
Colorado Kidney Care, Denver, Colorado, United States
DaVita Clinical Research, Middlebury, Connecticut, United States
PACT Kidney Care, Orange, Connecticut, United States
US Renal Care - Fort Myers South, Fort Myers, Florida, United States
Nephrology & Hypertension Specialists, Dalton, Georgia, United States
St. Clair Nephrology Research, Shelby, Michigan, United States
DaVita Clinical Research Edina, Edina, Minnesota, United States
Johnson County Clinical Trials, Kansas City, Missouri, United States
DaVita Clinical Research, Las Vegas, Nevada, United States
R1 Therapeutics Clinical Trial Site, Albuquerque, New Mexico, United States
NY Kidney & Hypertension Medicine, Ridgewood, New York, United States
US Renal Care - Alexis, Toledo, Ohio, United States
Sunbeam Research, Greenville, Texas, United States
DaVita Clinical Research, Houston, Texas, United States
Gamma Medical Research, McAllen, Texas, United States
R1 Therapeutics Clinical Trial Site, San Antonio, Texas, United States
US Renal Care - Westover Hills, San Antonio, Texas, United States
DaVita Clinical Research San Antonio, San Antonio, Texas, United States
R1 Therapeutics Clinical Trial Site, Waxahachie, Texas, United States
DaVita Clinical Research Norfolk, Norfolk, Virginia, United States
R1 Therapeutics Clinical Trial Site, Beijing, Beijing Municipality, China
R1 Therapeutics Clinical Trial Site, Beijing, Beijing Municipality, China
R1 Therapeutics Clinical Trial Site, Zhengzhou, Henan, China
R1 Therapeutics Clinical Trial Site, Nanjing, Jiangsu, China
R1 Therapeutics Clinical Trial Site, Nanjing, Jiangsu, China
R1 Therapeutics Clinical Trial Site, Shanghai, Shanghai Municipality, China
R1 Therapeutics Clinical Trial Site, Chengdu, Sichuan, China